Planegg / Munich, Germany (Press Release) – MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) today announced that it has added a second patent with US Patent Number 9,200,061 to its lawsuit against Janssen Biotech, and Genmab, A/S. This patent claims methods of treating hema­to­logic cancer asso­ci­ated with the undesired presence of CD38-positive cells by admin­istering anti­bodies that bind to a specific region of the target molecule, CD38. In a hearing that took place on Feb­ru­ary 6, 2017 the District Court granted MorphoSys's request to add the 9,200,061 patent to the case.

On April 4, 2016 MorphoSys filed a lawsuit in the United States (U.S.) District Court of Delaware against Janssen Biotech, and Genmab, A/S for patent infringement of U.S. Patent Number 8,263,746.

By its complaint, MorphoSys seeks redress for infringement by Janssen's and Genmab's dara­tu­mu­mab, a CD38-directed mono­clonal anti­body in­di­cated for the treat­ment of cer­tain patients with multiple myeloma. Janssen Biotech obtained FDA approval on dara­tu­mu­mab and mar­kets the prod­uct as Darzalex(R) in the U.S. and other countries. MorphoSys con­tinues to de­vel­op MOR202, its own inves­ti­ga­tional human anti­body to CD38, for the treat­ment of cancer, in­­clud­ing multiple myeloma.

About MorphoSys

MorphoSys devel­oped HuCAL, the most suc­cess­ful anti­body library tech­nology in the pharma­ceu­tical industry. By suc­cess­fully applying this and other patented tech­nolo­gies, MorphoSys has be­come a leader in the field of thera­peutic anti­bodies, one of the fastest-growing drug classes in human health­care.

Together with its pharma­ceu­tical partners, MorphoSys has built a thera­peutic pipe­line of more than 100 human anti­body drug can­di­dates for the treat­ment of cancer, rheumatoid arthritis, and Alzheimer's dis­ease, to name just a few. With its ongoing com­mitment to new anti­body tech­nology and drug devel­op­ment, MorphoSys is focused on making the health­care prod­ucts of tomorrow. MorphoSys is listed on the Frankfurt Stock Ex­change under the symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com.

HuCAL(R), HuCAL GOLD(R), HuCAL PLATINUM(R), CysDisplay(R), RapMAT(R), arYla(R), Ylanthia(R), 100 billion high poten­tials(R), Slonomics(R), Lanthio Pharma(R) and LanthioPep(R) are registered trademarks of the MorphoSys Group.

Darzalex(R) is a registered trademark of Johnson & Johnson.

This communication con­tains cer­tain for­ward-looking state­ments con­cern­ing the MorphoSys group of com­pa­nies. The for­ward-looking state­ments con­tained herein rep­re­sent the judg­ment of MorphoSys as of the date of this release and in­volve­ risks and un­cer­tain­ties. Should actual con­di­tions differ from the Com­pany's assump­tions, actual results and actions may differ from those antic­i­pated. MorphoSys does not in­tend to update any of these for­ward-looking state­ments as far as the wording of the relevant press release is con­cerned.

Source: MorphoSys.